Creating new ways to trigger immune responses in melanoma and kidney cancer.
Official title: Project III: Engineering immunogenic cell death in melanoma and renal cell carcinoma.
Funded at Sloan-Kettering Inst Can Research · NIH-10911896 · Data updated 2026-11-12
This study is looking at new ways to help people with melanoma and kidney cancer by using special treatments that boost the immune system, which might lead to better and longer-lasting results from their current therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 16, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $520,435 |
| NIH project number | 5U54CA274492-03 |
| Project ID | NIH-10911896 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with melanoma or renal cell carcinoma who have not responded adequately to current treatments.
✕Less likely to help
Patients with cancers other than melanoma or renal cell carcinoma may not receive any benefit from this research.
What this research studies
This research focuses on developing innovative immunotherapy strategies to improve treatment responses in patients with melanoma and renal cell carcinoma. The approach involves inducing a specific type of cell death that activates the immune system, potentially leading to better long-term outcomes. By exploring mechanisms like necroptosis and pyroptosis, the researchers aim to enhance the effectiveness of existing therapies, particularly immune checkpoint inhibitors. Patients may benefit from new treatment options that could lead to more durable responses to cancer therapy.
Why it matters
Potential benefit: If successful, this research could provide patients with more effective immunotherapy options that lead to longer-lasting cancer control.
How similar studies have gone: Other research has shown promising results using similar immunotherapy approaches, indicating potential for success in this area.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Cheng, Emily H — Sloan-Kettering Inst Can Research
- Study coordinator: Cheng, Emily H
Related research
Other NIH-funded projects on the same topics.
-
Engineering immunogenic cell death to boost melanoma and kidney cancer therapy
This grant supports research aimed at making melanoma and kidney cancer cells die in a way that triggers a stronger immune response in patients.
-
Making melanoma and kidney cancer cell death trigger stronger immune responses
This project aims to reprogram how melanoma and renal cell carcinoma cells die so their death sparks a bigger immune attack and helps more patients benefit from immunotherapy.
-
Understanding how kidney cancer spreads to bone and how to fight it
A patient-focused look at how clear cell renal cell carcinoma spreads to bone and how new treatments might help people with advanced disease.
-
Improve precision medicine for kidney cancer in people of African descent
A research project will explore why kidney cancer affects people of African ancestry differently and how to use genomics to guide better treatments.
-
Prognostic test to predict metastasis in clear cell kidney cancer
A new 12-marker biomarker test for people with clear cell renal cell carcinoma may help doctors predict which patients are at higher risk of metastasis.
-
Defining metabolic targets in kidney cancer for new treatments
A cancer-focused project is exploring how kidney cancer uses metabolism so doctors can find new, targeted ways to treat it.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.